Loading…
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-132M | $-120M | $-95M | -46.3% | - | - |
| 2024 | $0M | $-104M | $-86M | $-70M | -25.2% | - | - |
| 2023 | $0M | $-80M | $-69M | $-51M | -33.8% | - | - |
| 2022 | $0M | $-59M | $-55M | $-51M | -21.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 58.93 | 79.94 | 104.18 | 132.76 |
| Operating Income | -58.93 | -79.94 | -104.18 | -132.76 |
| EBITDA | -58.63 | -79.59 | -103.66 | -132.22 |
| EBIT | -58.93 | -79.94 | -104.18 | -132.76 |
| Pretax Income | -55.33 | -69.13 | -86.48 | -119.95 |
| Net Income | -55.33 | -69.13 | -86.48 | -119.95 |
| Net Income Common Stockholders | -55.33 | -69.13 | -86.48 | -119.95 |
| Total Expenses | 58.93 | 79.94 | 104.18 | 132.76 |
| Interest Income | 3.65 | 10.81 | 17.70 | 12.81 |
| Research And Development | 43.01 | 62.52 | 80.08 | 102.93 |
| Selling General And Administration | 15.92 | 17.43 | 24.10 | 29.83 |
| Normalized EBITDA | -58.63 | -79.59 | -103.66 | -132.22 |
| Normalized Income | -55.33 | -69.13 | -86.48 | -119.95 |
| Basic EPS | -1.32 | -1.62 | -1.51 | 0 |
| Diluted EPS | -1.32 | -1.62 | -1.51 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -55.33 | -69.13 | -86.48 | -119.95 |
| Reconciled Depreciation | 0.30 | 0.36 | 0.52 | 0.55 |
| Net Interest Income | 3.65 | 10.81 | 17.70 | 12.81 |
| Net Income From Continuing And Discontinued Operation | -55.33 | -69.13 | -86.48 | -119.95 |
| Total Operating Income As Reported | -58.93 | -79.94 | -104.18 | -132.76 |
| Diluted Average Shares | 41.88 | 42.70 | 57.22 | 0 |
| Basic Average Shares | 41.88 | 42.70 | 57.22 | 0 |
| Diluted NI Availto Com Stockholders | -55.33 | -69.13 | -86.48 | -119.95 |
| Net Income Including Noncontrolling Interests | -55.33 | -69.13 | -86.48 | -119.95 |
| Net Income Continuous Operations | -55.33 | -69.13 | -86.48 | -119.95 |
| Other Income Expense | -0.05 | -0.04 | 0 | 0 |
| Other Non Operating Income Expenses | -0.05 | -0.04 | 0 | 0 |
| Net Non Operating Interest Income Expense | 3.65 | 10.81 | 17.70 | 12.81 |
| Interest Income Non Operating | 3.65 | 10.81 | 17.70 | 12.81 |
| General And Administrative Expense | 15.92 | 17.43 | 24.10 | 29.83 |
| Other Gand A | 15.92 | 17.43 | 24.10 | 29.83 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc.this co. | TYRA | $2.0B | - | 7.00 | -46.3% | -11.87 |
| GRAIL, Inc. | GRAL | $2.1B | - | 0.78 | -15.8% | -3.15 |
| Mineralys Therapeutics, Inc. | MLYS | $2.1B | - | 3.22 | -23.9% | -8.50 |
| Ocular Therapeutix, Inc. | OCUL | $2.0B | - | 3.04 | -40.6% | -5.06 |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.0B |
| 7.38 |
| 3.48 |
| 49.4% |
| 12.59 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | - | 9.68 | -23.3% | -32.27 |
| Pediatrix Medical Group, Inc. | MD | $1.9B | 11.57 | 2.21 | 19.1% | 7.93 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | - | 5.42 | -2.0% | -86.99 |
| Omnicell, Inc. | OMCL | $1.9B | 828.21 | 1.38 | 0.2% | 18.60 |
| Peer Median | - | 11.57 | 3.13 | -8.9% | -4.10 | |